LGND

111.67

0.04% -0.04

Dopo l'orario di chiusura: 111.67

Ligand Pharmaceuticals Inc (LGND)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario Storia dei dividendi

Precedente Chiudi:

$111.71

Aprire:

$110.87

Volume 24 ore:

124.18K

Relative Volume:

1.17

Capitalizzazione di mercato:

$2.11B

Reddito:

$118.31M

Utile/perdita netta:

$96.34M

Rapporto P/E:

77.55

EPS:

1.44

Flusso di cassa netto:

$-19.62M

1 W Prestazione:

-9.56%

1M Prestazione:

+4.96%

6M Prestazione:

+29.76%

1 anno Prestazione:

+93.13%

Intervallo 1D:

$109.44

$113.04

Intervallo di 1 settimana:

$109.44

$125.76

Portata 52W:

$57.00

$129.90

Ligand Pharmaceuticals Inc Stock (LGND) Company Profile

Nome

Ligand Pharmaceuticals Inc

Settore

Healthcare (1196)

Industria

Biotechnology (683)

Telefono

858-550-7500

Indirizzo

3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA

Dipendente

Cinguettio

@Ligand_LGND

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

LGND's Discussions on Twitter

Confronta LGND con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
LGND	111.67	2.11B	118.31M	96.34M	-19.62M	1.44
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2021-04-14	Ripresa	Stephens	Overweight
2021-02-04	Reiterato	H.C. Wainwright	Buy
2020-10-06	Iniziato	Barclays	Overweight
2020-03-24	Downgrade	Argus	Buy → Hold
2020-03-10	Iniziato	Guggenheim	Neutral
2020-02-06	Iniziato	The Benchmark Company	Buy
2019-09-19	Aggiornamento	Barclays	Equal Weight → Overweight
2019-06-11	Iniziato	Barclays	Equal Weight
2019-05-03	Reiterato	H.C. Wainwright	Buy
2019-03-06	Reiterato	H.C. Wainwright	Buy
2018-10-29	Aggiornamento	ROTH Capital	Neutral → Buy
2018-10-02	Reiterato	H.C. Wainwright	Buy
2018-09-11	Reiterato	Argus	Buy
2018-08-17	Iniziato	Goldman	Neutral
2018-08-08	Downgrade	ROTH Capital	Buy → Neutral
2018-06-21	Iniziato	Argus	Buy
2017-12-27	Reiterato	H.C. Wainwright	Buy
2017-09-05	Ripresa	H.C. Wainwright	Buy
2016-10-05	Reiterato	H.C. Wainwright	Buy
2016-08-05	Downgrade	Deutsche Bank	Hold → Sell
2016-03-11	Iniziato	Sidoti	Buy
2016-03-03	Iniziato	H.C. Wainwright	Buy

Mostra tutto

Ligand Pharmaceuticals Inc Borsa (LGND) Ultime notizie

Nov 16, 2024

Ligand Pharmaceuticals (NASDAQ:LGND) Shareholders Should Be Cautious Despite Solid Earnings - Yahoo Finance

Nov 16, 2024

Nov 14, 2024

Janus Henderson Group PLC Expands Stake in Ligand Pharmaceuticals Inc - GuruFocus.com

Nov 14, 2024

Ligand Pharmaceuticals to Present at Stifel 2024 Healthcare Conference | LGND Stock News - StockTitan

Nov 14, 2024

Nov 12, 2024

Royal Bank of Canada Forecasts Strong Price Appreciation for Ligand Pharmaceuticals (NASDAQ:LGND) Stock - MarketBeat

Nov 12, 2024

Ligand Pharmaceuticals (NASDAQ:LGND) Given New $150.00 Price Target at Barclays - Defense World

Nov 12, 2024

Ligand Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com Canada

Nov 12, 2024

Nov 11, 2024

LGND: 3Q Sales Surprise to the Upside - Zacks Small Cap Research

Nov 11, 2024

Lisanti Capital Growth LLC Makes New Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat

Nov 11, 2024

Nov 09, 2024

Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Expected to Rise, Benchmark Analyst Says - MarketBeat

Nov 09, 2024

Ligand Pharmaceuticals (NASDAQ:LGND) Shares Down 7.7%Should You Sell? - MarketBeat

Nov 09, 2024

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024

Ligand Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Nov 09, 2024

Villere ST Denis J & Co. LLC Lowers Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat

Nov 09, 2024

Earnings call: Ligand reports robust Q3 growth, raises 2024 forecast - Investing.com India

Nov 09, 2024

Nov 08, 2024

Earnings call: Ligand reports robust Q3 growth, raises 2024 forecast By Investing.com - Investing.com Nigeria

Nov 08, 2024

Ligand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $150.00 at Barclays - MarketBeat

Nov 08, 2024

Oppenheimer Forecasts Strong Price Appreciation for Ligand Pharmaceuticals (NASDAQ:LGND) Stock - MarketBeat

Nov 08, 2024

A Closer Look at 7 Analyst Recommendations For Ligand Pharmaceuticals - Benzinga

Nov 08, 2024

Ligand Pharmaceuticals (NASDAQ:LGND) Given Buy Rating at HC Wainwright - MarketBeat

Nov 08, 2024

Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Intrinsic Value Is Potentially 99% Above Its Share Price - Yahoo Finance

Nov 08, 2024